Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

被引:303
|
作者
Zhanel, George G. [1 ,7 ]
Golden, Alyssa R. [1 ]
Zelenitsky, Sheryl [2 ]
Wiebe, Karyn [2 ]
Lawrence, Courtney K. [2 ]
Adam, Heather J. [1 ,3 ]
Idowu, Temilolu [4 ]
Domalaon, Ronald [4 ]
Schweizer, Frank [1 ,4 ]
Zhanel, Michael A. [1 ]
Lagace-Wiens, Philippe R. S. [1 ,3 ]
Walkty, Andrew J. [1 ,3 ]
Noreddin, Ayman [5 ]
Lynch, Joseph P., III [6 ]
Karlowsky, James A. [1 ,3 ]
机构
[1] Univ Manitoba, Dept Med Microbiol & Infect Dis, Max Rady Coll Med, Fac Hlth Sci, Winnipeg, MB, Canada
[2] Univ Manitoba, Coll Pharm, Fac Hlth Sci, Winnipeg, MB, Canada
[3] Shared Hlth, Diagnost Serv, Winnipeg, MB, Canada
[4] Univ Manitoba, Dept Chem, Fac Sci, Winnipeg, MB, Canada
[5] Univ Sharjah, Coll Pharm, Sharjah, U Arab Emirates
[6] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm Crit Care Allergy & Clin Immunol, Los Angeles, CA 90095 USA
[7] Clin Microbiol Hlth Sci Ctr, MS673-820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada
关键词
VITRO ANTIMICROBIAL ACTIVITY; PSEUDOMONAS-AERUGINOSA; CEFTAZIDIME-AVIBACTAM; S-649266;
D O I
10.1007/s40265-019-1055-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cefiderocol is an injectable siderophore cephalosporin discovered and being developed by Shionogi & Co., Ltd., Japan. As with other -lactam antibiotics, the principal antibacterial/bactericidal activity of cefiderocol occurs by inhibition of Gram-negative bacterial cell wall synthesis by binding to penicillin binding proteins; however, it is unique in that it enters the bacterial periplasmic space as a result of its siderophore-like property and has enhanced stability to -lactamases. The chemical structure of cefiderocol is similar to both ceftazidime and cefepime, which are third- and fourth-generation cephalosporins, respectively, but with high stability to a variety of -lactamases, including AmpC and extended-spectrum -lactamases (ESBLs). Cefiderocol has a pyrrolidinium group in the side chain at position 3 like cefepime and acarboxypropanoxyimino group in the side chain at position 7 of the cephem nucleus like ceftazidime. The major difference in the chemical structures of cefiderocol, ceftazidime and cefepime is the presence of a catechol group on the side chain at position 3. Together with the high stability to -lactamases, including ESBLs, AmpC and carbapenemases, the microbiological activity of cefiderocol against aerobic Gram-negative bacilli is equal to or superior to that of ceftazidime-avibactam and meropenem, and it is active against a variety of Ambler class A, B, C and D -lactamases. Cefiderocol is also more potent than both ceftazidime-avibactam and meropenem versus Acinetobacter baumannii, including meropenem non-susceptible and multidrug-resistant (MDR) isolates. Cefiderocol's activity against meropenem-non-susceptible and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriales is comparable or superior to ceftazidime-avibactam. Cefiderocol is also more potent than both ceftazidime-avibactam and meropenem against all resistance phenotypes of Pseudomonas aeruginosa and against Stenotrophomonas maltophilia. The current dosing regimen being used in phase III studies is 2g administered intravenously every 8h (q8h) using a 3-h infusion. The pharmacokinetics of cefiderocol are best described by a three-compartment linear model. The mean plasma half-life (t(1/2)) was similar to 2.3h, protein binding is 58%, and total drug clearance ranged from 4.6-6.0 L/h for both single- and multi-dose infusions and was primarily renally excreted unchanged (61-71%). Cefiderocol is primarily renally excreted unchanged and clearance correlates with creatinine clearance. Dosage adjustment is thus required for both augmented renal clearance and in patients with moderate to severe renal impairment. In vitro and in vivo pharmacodynamic studies have reported that as with other cephalosporins the pharmacodynamic index that best predicts clinical outcome is the percentage of time that free drug concentrations exceed the minimum inhibitory concentration (%fT>MIC). In vivo efficacy of cefiderocol has been studied in a variety of humanized drug exposure murine and rat models of infection utilizing a variety of MDR and extremely drug resistant strains. Cefiderocol has performed similarly to or has been superior to comparator agents, including ceftazidime and cefepime. A phase II prospective, multicenter, double-blind, randomized clinical trial assessed the safety and efficacy of cefiderocol 2000mg q8h versus imipenem/cilastatin 1000mg q8h, both administered intravenously for 7-14days over 1h, in the treatment of complicated urinary tract infection (cUTI, including pyelonephritis) or acute uncomplicated pyelonephritis in hospitalized adults. A total of 452 patients were initially enrolled in the study, with 303 in the cefiderocol arm and 149 in the imipenem/cilastatin arm. The primary outcome measure was a composite of clinical cure and microbiological eradication at the test-of-cure (TOC) visit, that is, 7days after the end of treatment in the microbiological intent-to-treat (MITT) population. Secondary outcome measures included microbiological response per pathogen and per patient at early assessment (EA), end of treatment (EOT), TOC, and follow-up (FUP); clinical response per pathogen and per patient at EA, EOT, TOC, and FUP; plasma, urine and concentrations of cefiderocol; and the number of participants with adverse events. The composite of clinical and microbiological response rates was 72.6% (183/252) for cefiderocol and 54.6% (65/119) for imipenem/cilastatin in the MITT population. Clinical response rates per patient at the TOC visit were 89.7% (226/252) for cefiderocol and 87.4% (104/119) for imipenem/cilastatin in the MITT population. Microbiological eradication rates were 73.0% (184/252) for cefiderocol and 56.3% (67/119) for imipenem/cilastatin in the MITT population. Additionally, two phase III clinical trials are currently being conducted by Shionogi & Co., Ltd., Japan. The two trials are evaluating the efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens and evaluating the efficacy of cefiderocol in the treatment of adults with hospital-acquired bacterial pneumonia, ventilator-associated pneumonia or healthcare-associated pneumonia caused by Gram-negative pathogens. Cefiderocol appears to be well tolerated (minor reported adverse effects were gastrointestinal and phlebitis related), with a side effect profile that is comparable to other cephalosporin antimicrobials. Cefiderocol appears to be well positioned to help address the increasing number of infections caused by carbapenem-resistant and MDR Gram-negative bacilli, including ESBL- and carbapenemase-producing strains (including metallo--lactamase producers). A distinguishing feature of cefiderocol is its activity against resistant P. aeruginosa, A. baumannii, S. maltophilia and Burkholderia cepacia.
引用
收藏
页码:271 / 289
页数:19
相关论文
共 50 条
  • [21] Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
    Bonomo, Robert A.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 : 519 - 520
  • [22] Save Carbapenem Campaign: Assessment of Antibiotic Combinations Against Multidrug-Resistant Gram-Negative Bacilli
    Tellis, Rouchelle
    Ignatius, Anand
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2020, 41 : S381 - S381
  • [23] Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens
    Choby, Jacob E.
    Ozturk, Tugba
    Satola, Sarah W.
    Jacob, Jesse T.
    Weiss, David S.
    LANCET INFECTIOUS DISEASES, 2021, 21 (05): : 597 - 598
  • [24] In vitro activity of cefiderocol, a siderophore cephalosporin, against carbapenem-resistant hypervirulent Klebsiella pneumoniae in China
    Zhao, Jiankang
    Pu, Danni
    Li, Ziyao
    Liu, Xinmeng
    Zhang, Yulin
    Wu, Yongli
    Zhang, Feilong
    Li, Chen
    Zhuo, Xianxia
    Lu, Binghuai
    Cao, Bin
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023,
  • [25] Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
    Pybus, Christine A.
    Felder-Scott, Christina
    Obuekwe, Victor
    Greenberg, David E.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (02)
  • [26] Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
    Giacobbe, Daniele Roberto
    Ciacco, Eugenio
    Girmenia, Corrado
    Pea, Federico
    Rossolini, Gian Maria
    Sotgiu, Giovanni
    Tascini, Carlo
    Tumbarello, Mario
    Viale, Pierluigi
    Bassetti, Matteo
    INFECTION AND DRUG RESISTANCE, 2020, 13 : 4697 - 4711
  • [27] Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms
    Basaran, Sena Nur
    Oksuz, Lutfiye
    ARCHIVES OF MICROBIOLOGY, 2025, 207 (05)
  • [28] Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador
    Soria-Segarra, Claudia
    Soria-Segarra, Carmen
    Molina-Matute, Marcos
    Agreda-Orellana, Ivanna
    Nunez-Quezada, Tamara
    Cevallos-Apolo, Kerly
    Miranda-Ayala, Marcela
    Salazar-Tamayo, Grace
    Galarza-Herrera, Margarita
    Vega-Hall, Victor
    Villacis, Jose E.
    Gutierrez-Fernandez, Jose
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [29] Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador
    Claudia Soria-Segarra
    Carmen Soria-Segarra
    Marcos Molina-Matute
    Ivanna Agreda-Orellana
    Tamara Núñez-Quezada
    Kerly Cevallos-Apolo
    Marcela Miranda-Ayala
    Grace Salazar-Tamayo
    Margarita Galarza-Herrera
    Victor Vega-Hall
    José E. Villacis
    José Gutiérrez-Fernández
    BMC Infectious Diseases, 24
  • [30] Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria
    Lewis, Russell E.
    Palombo, Marta
    Diani, Erica
    Secci, Benedetta
    Gibellini, Davide
    Gaibani, Paolo
    CELLS, 2024, 13 (16)